Vielight at SOMA 2026: Operator Brain Health in Special Operations Medicine

With brain health an increasingly central question in SOF medical readiness, non-invasive options like Vielight are entering serious conversation across the field, including at SOMA 2026 in Raleigh.

Why SOF brain health is increasingly on the agenda

Brain health is now central to SOF medical readiness. The conversation across USSOCOM, the U.S. Department of Veterans Affairs (VA), and allied SOF commands has shifted measurably over the past 18 months. Repeated blast exposure, cumulative head-impact load, prolonged sleep restriction, traumatic brain injury (TBI), post-traumatic stress (PTSD-related symptoms), and the cognitive cost of high-tempo deployment cycles are no longer edge-of-program concerns — they are central to how SOF medical providers think about long-term operator health, retention, and post-service quality of life. SOMA brings together the people closest to those questions: the medics on the teams, the physicians running recovery and reconditioning programs, and the researchers publishing the data.

What intranasal-transcranial photobiomodulation (itPBM) is

Photobiomodulation (PBM), sometimes referred to in consumer settings as red light therapy, uses specific wavelengths of low-level red and near-infrared light to interact with cellular targets. Vielight pioneered the intranasal-transcranial approach, delivering 810 nm near-infrared light pulsing at 40 Hz through both an intranasal applicator and transcranial LED clusters positioned over key brain network regions, including hubs of the default mode network. The 810 nm wavelength was selected because it pairs deeper transcranial penetration with peak absorption at cytochrome c oxidase, the mitochondrial enzyme central to ATP production. This dual-pathway design underlies Vielight’s 36 international patents and is the same configuration used in independent research at Harvard, Boston University, UCSF, NYU, the University of Utah, and Brigham Young University. Vielight’s flagship clinical-research devices include the Vielight Neuro Pro 2 and the Neuro Gamma family used across the published trials below.

Peer-reviewed evidence relevant to the SOF community

Recent publications speak directly to the questions SOF medical providers raise first about TBI, head-impact exposure, and post-traumatic stress symptoms:

• Football / repetitive head impacts (2026). Lindsey HM, Esopenko C, Jain D, et al. “Transcranial Photobiomodulation Promotes Neurological Resilience in Current Collegiate American Football Players Exposed to Repetitive Head Acceleration Events.” Journal of Neurotrauma, 2026 (doi:10.1177/08977151251403554). A randomized, double-blind, sham-controlled trial of 26 NCAA Division I football players. Across a 16-week season, diffusion MRI imaging in the itPBM group remained microstructurally stable, while the sham group showed marked changes consistent with neuroinflammation and reduced white matter integrity. This is the closest published research analogue currently available to the head-impact exposure profile some SOF operators carry. (See Vielight’s full study summary.)
• Long COVID brain fog (2026). The Lancet eClinicalMedicine, ClinicalTrials.gov NCT05857124. A randomized, double-blind, sham-controlled pilot trial in 43 U.S. adults reported measurable improvements in objective cognitive performance using a home-based itPBM protocol with the Vielight Neuro RX Gamma.
• Firefighter pilot (2025). Tate DF, Lindsey HM, Wilde EA. “Transcranial Photobiomodulation and Firefighter Health and Wellness: A Single-Arm, Open-Label Pilot Study.” Photobiomodulation, Photomedicine, and Laser Surgery, 2025; 43(8):337–345 (doi:10.1177/15578550251362096). Conducted at the University of Utah TBI and Concussion Center and the George E. Whalen VA Medical Center in 14 active firefighters, the pilot reported pre-to-post reductions on the PCL-5 self-report measure following an itPBM protocol with the Vielight Neuro Gamma.
• DoD-funded TBI trial (in progress). “Shining Light on Trauma: Treatment of Chronic TBI to Improve Psychological Health Using Photobiomodulation in Service Members, Veterans, and First Responders.” A multi-arm, randomized, controlled trial led by Elisabeth Wilde, PhD and Carrie Esopenko, PhD at the University of Utah TBI and Concussion Center in partnership with NYU. Funded by a $4.6M U.S. Department of Defense grant, the four-year study (September 2025 – August 2029) will recruit 300 service members, veterans, and first responders with persistent mild TBI symptoms.

Conversations at SOMA 2026

Across the four days in Raleigh, conversations centered on the practical questions that surface when a new modality enters the operator-care pipeline: How does it integrate alongside existing care without adding workflow burden? What does the safety profile look like for self-administered use in garrison or between deployments? What does the published evidence currently show, and where are the open questions the next wave of research is designed to answer? The operator-population focus of SOMA and the cross-pollination between active-duty medics, VA clinicians, and academic researchers in the room made it a uniquely high-signal venue for those discussions.

What’s next

Vielight will continue to work alongside the SOF medical community, the U.S. Department of Veterans Affairs, the Lovell Government Services federal supply channel, and allied research institutions on the science of brain health for those who serve. Updates on the DoD-funded itPBM TBI trial, additional findings from the University of Utah football cohort, and ongoing veteran-focused research will be published as they reach peer review.